New Delhi: The Indian Council of Medical Research (ICMR) will begin a study to study the effectiveness of AstraZeneca’s Covishield and Bharat Biotech’s Covaxin from subsequent week.
This is the primary of its form study because the launch of these vaccines within the nation, the survey will study the effectiveness in stopping development of COVID-19 right into a severe form, as per a report by PTI.
According to Dr Tarun Bhatnagar, a senior scientist at ICMR’s National Institute of Epidemiology (NIE) in Chennai practically 4,000 individuals above the age of 45 years who’ve taken both one or each doses of any of these two vaccines will probably be reviewed.
“As a part of the study we will take people who are COVID-19 positive and hospitalised and compare their vaccination status with those who have tested COVID negative. The aim is to assess how effective vaccination is in preventing progression of the disease into a severe form,” Bhatnagar instructed PTI.
The cumulative vaccine doses administered within the nation has crossed 20 crore thus far.
The authorities has additionally been stressing on the necessity to put on a masks and adherence to different COVID protocols.
India, thus far, has authorised the use of three vaccines against COVID-19. These embrace Pune-based Serum Institute’s Covishield and Bharat Biotech’s Covaxin.
Russia’s Sputnik V is the third vaccine to get approval from the Drug Controller General of India (DCGI) for Emergency Use Authorisation and has been utilized in just a few non-public hospitals thus far.
